search
Back to results

Imaging of the Esophagus Using a SECM Capsule

Primary Purpose

Eosinophilic Esophagitis, Barrett Esophagus

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
SECM capsule
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Eosinophilic Esophagitis focused on measuring EoE, Eosinophilic Esophagitis, Barrett's Esophagus, Capsule, SECM, Tethered Capsule Endomicroscopy

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 12 years of age or older undergoing endoscopic biopsy for evaluation of EoE
  • Able to give informed consent

Exclusion Criteria:

  • Inability to swallow pills and capsules
  • Esophageal fistula and/or esophageal strictures with a stricture diameter that is smaller than the diameter of the capsule

Sites / Locations

  • Massachusetts General HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

SECM capsule imaging

Arm Description

Subject will swallow the SECM capsule and the imaging of the esophagus will be performed using a SECM optical system

Outcomes

Primary Outcome Measures

Feasibility of imaging of the Esophagus using a SECM Capsule
comparing SECM imaging of the esophagus obtained with a SECM capsule to histopathology.

Secondary Outcome Measures

Full Information

First Posted
May 23, 2018
Last Updated
January 20, 2023
Sponsor
Massachusetts General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03546660
Brief Title
Imaging of the Esophagus Using a SECM Capsule
Official Title
Imaging of the Esophagus Using a SECM Capsule
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2024 (Anticipated)
Primary Completion Date
December 30, 2025 (Anticipated)
Study Completion Date
December 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this validation study is to compare Spectrally Encoded Confocal Microscopy (SECM) Tethered Capsule Endoscopy (TCE) diagnosis of Eosinophilic Esophagitis to that of standard of care endoscopic biopsy.
Detailed Description
Eosinophilic esophagitis is an inflammatory condition of the esophagus that occurs in response to certain foods or allergens. Approximately 300,000 people in the US have EoE, the incidence of newly diagnosed EoE is ~30,000/year, and EoE is found in 5-10% of all patients undergoing upper endoscopy. EoE is associated with debilitating symptoms, and is a common cause of dysphagia, strictures, and food impaction; it may even lead to esophageal perforation. Because of the impact of EoE on quality of life as well as the concern that this disease may progress to esophageal fibrosis with unknown long-term risks, experts recommend that EoE be treated until symptoms and eosinophilic infiltrate are resolved. Because the only objective method for diagnosing EoE is histopathologic assessment of multiple upper endoscopic biopsies, the processes of monitoring the esophagus during therapy and the food reintroduction involve a high number of repeat endoscopies. This process is both time consuming and frustrating for patients and their families. Because the endoscopic biopsy requires conscious sedation, it is also costly, exceeding $1000 per procedure. Given the rapid increase in the number of patients with this disease, there is a compelling need for a less invasive and more cost-effective means of identifying eosinophils in the esophagus. Based on the extensive experience with Optical Coherence Tomography (OCT) and OFDI, the investigators at Tearney laboratory at MGH have developed a spectrally encoded confocal microscopy (SECM) technology that is able to acquire images at significantly higher frame rates than standard confocal microscopy. This SECM capability enables imaging of large portions of the esophagus at 2-µm resolution in realistic procedure times. Furthermore, the investigators at Tearney laboratory have created a tethered capsule SECM device that can be swallowed and used for EoE screening. The investigators at Tearney laboratory lab performed a pilot study using a SECM capsule on 58 subjects (2013-P-000863). The imaging was successful with no adverse or unanticipated events. SECM endoscopy capsule is similar to the approved endoscopy capsule. A total of sixty (60) subjects will be recruited for this study. The imaging of the esophagus will be obtained. Subjects will not be sedated for the procedure. The images obtained by the SECM capsule will be compared to the images obtained by the clinical endoscopy and biopsy. SECM imaging will be used for research purposes only and will not be used for diagnosis purposes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Eosinophilic Esophagitis, Barrett Esophagus
Keywords
EoE, Eosinophilic Esophagitis, Barrett's Esophagus, Capsule, SECM, Tethered Capsule Endomicroscopy

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SECM capsule imaging
Arm Type
Experimental
Arm Description
Subject will swallow the SECM capsule and the imaging of the esophagus will be performed using a SECM optical system
Intervention Type
Device
Intervention Name(s)
SECM capsule
Intervention Description
Subjects will swallow a SECM capsule and the SECM imaging will be performed
Primary Outcome Measure Information:
Title
Feasibility of imaging of the Esophagus using a SECM Capsule
Description
comparing SECM imaging of the esophagus obtained with a SECM capsule to histopathology.
Time Frame
10 minutes (roughly the amount of time it takes to image the esophagus via SECM capsule)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 12 years of age or older undergoing endoscopic biopsy for evaluation of EoE Able to give informed consent Exclusion Criteria: Inability to swallow pills and capsules Esophageal fistula and/or esophageal strictures with a stricture diameter that is smaller than the diameter of the capsule
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anna Gao, RN
Phone
617-643-6092
Email
Tearneylabtrials@partners.org
First Name & Middle Initial & Last Name or Official Title & Degree
Anita Chung, RN
Phone
617-724-4515
Email
Tearneylabtrials@partners.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guillermo Tearney, MD, PhD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Indira Balmasheva, RN
Phone
617-643-6092
Email
Tearneylabtrials@partners.org
First Name & Middle Initial & Last Name & Degree
Anita Chung, RN
Phone
617-724-4515
Email
TEARNEYLABTRIALS@partners.org

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Imaging of the Esophagus Using a SECM Capsule

We'll reach out to this number within 24 hrs